CRIS earnings analysis
What we found in CRIS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q text does not include the income statement, balance sheet, cash-flow statement, or MD&A needed to assess current-quarter revenue, margins, EPS, working capital, and cash flow; those metrics are therefore unavailable. Liquidity improved through the August 2026 offering, which produced approximately $4.8 million of estimated net proceeds, but management expects the combined $9.9 million of cash and proceeds to fund operations only into the fourth quarter of 2026. The explicit going-concern conclusion, continuing funding needs, Nasdaq monitoring, and reverse-split liquidity concerns support a bearish assessment.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- $5.5M Public Offering Completed
- The August 2026 Public Offering generated approximately $5.5 million of gross proceeds, before fees and offering expenses, including the issuance of 335,001 shares and pre-funded warrants for up to 3,398,333 shares.
- Liquidity Supplemented by Financing
- Management estimates approximately $4.8 million of net offering proceeds after placement-agent fees and other expenses, supplementing $5.1 million of cash and cash equivalents at June 30, 2026.
- Disclosure Controls Remained Effective
- Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026, and reported no material control changes during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-Concern Doubt and Limited Runway
- The company identified conditions raising substantial doubt about its ability to continue as a going concern. It stated that $5.1 million of existing cash plus approximately $4.8 million of offering proceeds should fund operations only into the fourth quarter of 2026, and that cash is insufficient to support operations beyond 12 months from the filing date.
- Nasdaq Delisting Exposure
- Nasdaq compliance remains vulnerable despite the company regaining compliance with the minimum bid-price requirement on July 24, 2026. The company is subject to a one-year Discretionary Panel Monitor and cannot receive additional compliance-plan time for deficiencies arising during that period.
- Reverse Split May Reduce Liquidity
- The July 6, 2026 1-for-20 reverse stock split may reduce trading liquidity and increase odd-lot ownership. The filing notes that odd lots are holdings of less than 100 shares and may involve higher transaction costs.
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the supplied 10-Q text. Management states that $5.1 million of cash at June 30, 2026 plus approximately $4.8 million of net proceeds from the August 2026 Public Offering should fund operations into the fourth quarter of 2026.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Curis, Inc. reported no revenue for Q1 2026, missing the analyst expectations of $2,092,000. The company's net loss was $24.2 million, resulting in an EPS of -$1.25, a significant increase from the previous year's loss…
- 10-K · March 24, 2026
- Curis (CRIS) is a clinical-stage biotech focused on emavusertib (IRAK4/FLT3 inhibitor) and is concentrating development on a Phase 1/2 PCNSL combination with ibrutinib and a Phase 2 CLL combination with zanubrutinib.…
- 10-K · March 16, 2021
- Curis is an early-stage oncology biotech focused on developing CA-4948 (IRAK4 inhibitor) and CI-8993 (anti-VISTA antibody) while continuing to receive royalties and milestones from Genentech for Erivedge. The company…
- 10-Q · August 9, 2019
- Curis reported Q2 2019 revenue of $2.094 million (down from $2.358 million a year earlier) and a GAAP net loss of $7.213 million (net loss per share $0.22). Operating loss narrowed to $6.141 million from $7.860 million…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CRIS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever